Healthspan discussion on recent human trials of rapamycin (opens in new tab)

A discussion of human trials of rapamycin and a walk-through of 2025 studies specifically. The PEARL trial: the first major human data on weekly low-dose rapamycin Early cardiovascular benefits at low doses Emerging research on long COVID and chronic fatigue The mTOR pathway, explained simply What animal studies (ITP) show vs. what we’re now seeing in humans Dosing and bioavailability: why more isn’t always better A year of safety data, explained Trials to watch in 2026 and 2027 1 post - 1 pa...